Grünenthal and Akashi Therapeutics Inc. Announce Joint Drug Development Program for HT-100 in the Treatment of Patients with Duchenne Muscular Dystrophy (DMD)

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.